Alnylam's Amvuttra® (vutrisiran) Wins Landmark FDA Approval for Deadly Heart Disease, Fueling Significant Revenue Growth

In a pivotal moment for the company, the U.S. Food and Drug Administration (FDA) approved Alnylam's supplemental New Drug Application for Amvuttra® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This decision significantly expanded the drug's market, making it the first and only therapeutic approved in the U.S. to treat both ATTR-CM and the polyneuropathy associated with the disease, and was a key driver of the company's substantial revenue growth in 2025.